Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2025)

Mangoceuticals' Net Income towards Common Stockholders history spans 3 years, with the latest figure at -$3.1 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 57.24% to -$3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$21.2 million, a 135.89% decrease, with the full-year FY2025 number at -$21.8 million, down 129.47% from a year prior.
  • Net Income towards Common Stockholders hit -$3.1 million in Q4 2025 for Mangoceuticals, up from -$7.9 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for MGRX hit a ceiling of -$1.8 million in Q3 2023 and a floor of -$7.9 million in Q3 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$3.3 million across 3 years, with a median of -$2.5 million in 2023.
  • Biggest five-year swings in Net Income towards Common Stockholders: increased 24.13% in 2024 and later tumbled 245.02% in 2025.
  • Tracing MGRX's Net Income towards Common Stockholders over 3 years: stood at -$2.6 million in 2023, then grew by 24.13% to -$1.9 million in 2024, then plummeted by 57.24% to -$3.1 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for MGRX at -$3.1 million in Q4 2025, -$7.9 million in Q3 2025, and -$5.4 million in Q2 2025.